<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>阿基米德Biotech | wechat-feeds</title><link>http://Mzk0MzEzNjg4NQ.favicon.privacyhide.com/favicon.ico</link><description>专注生物医药长期逻辑，客观中立，深入浅出。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 18 Apr 2021 21:26:32 +0800</pubDate><image><url>http://Mzk0MzEzNjg4NQ.favicon.privacyhide.com/favicon.ico</url><title>阿基米德Biotech | wechat-feeds</title><link>http://Mzk0MzEzNjg4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>亢奋与幻觉：元气森林兴奋剂</title><link>https://mp.weixin.qq.com/s/y70i09XuTo-9VufKHMK72Q</link><description></description><content:encoded><![CDATA[亢奋与幻觉：元气森林兴奋剂]]></content:encoded><pubDate>Sat, 17 Apr 2021 19:42:35 +0800</pubDate></item><item><title>为何总有人提前抄高瓴作业？</title><link>https://mp.weixin.qq.com/s/0biXnGf8VWkFtZ3p7or_dQ</link><description></description><content:encoded><![CDATA[为何总有人提前抄高瓴作业？]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:08:20 +0800</pubDate></item><item><title>95%以上医药股都不值得投资，不幸的药企各有各的不幸</title><link>https://mp.weixin.qq.com/s/WnFSnZUoAZJaMTb6z1SshQ</link><description></description><content:encoded><![CDATA[95%以上医药股都不值得投资，不幸的药企各有各的不幸]]></content:encoded><pubDate>Tue, 13 Apr 2021 15:48:03 +0800</pubDate></item><item><title>一个赚钱心法</title><link>https://mp.weixin.qq.com/s/GMJNY5A4ZpxqbgBh9hy4Og</link><description></description><content:encoded><![CDATA[一个赚钱心法]]></content:encoded><pubDate>Mon, 12 Apr 2021 16:12:08 +0800</pubDate></item><item><title>内陆药企深深的无力感</title><link>https://mp.weixin.qq.com/s/IyFz85J2bjMGPL-vejzA2g</link><description></description><content:encoded><![CDATA[内陆药企深深的无力感]]></content:encoded><pubDate>Sun, 11 Apr 2021 13:54:44 +0800</pubDate></item><item><title>​500亿美瞳蓝海，比OK镜市场更大</title><link>https://mp.weixin.qq.com/s/XUNPZCCfhdskIB_U0PrG0w</link><description></description><content:encoded><![CDATA[​500亿美瞳蓝海，比OK镜市场更大]]></content:encoded><pubDate>Wed, 07 Apr 2021 21:21:29 +0800</pubDate></item><item><title>钱快烧完了，哪些创新药企大限将至</title><link>https://mp.weixin.qq.com/s/OMEbSkaap4AlGWAV0tBblA</link><description></description><content:encoded><![CDATA[钱快烧完了，哪些创新药企大限将至]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:53:58 +0800</pubDate></item><item><title>全市场最热赛道③：老药企与爱美客争当医美老大</title><link>https://mp.weixin.qq.com/s/oBzDw2sIcJN_uYr86gsMMg</link><description></description><content:encoded><![CDATA[全市场最热赛道③：老药企与爱美客争当医美老大]]></content:encoded><pubDate>Sun, 04 Apr 2021 20:00:35 +0800</pubDate></item><item><title>全市场最强赛道解读②：CXO还能涨几年？</title><link>https://mp.weixin.qq.com/s/e66KuVDOtqysZv6RqtYgEA</link><description></description><content:encoded><![CDATA[全市场最强赛道解读②：CXO还能涨几年？]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:24:18 +0800</pubDate></item><item><title>全市场最强赛道解读①：CXO七龙珠踏上巨头之路</title><link>https://mp.weixin.qq.com/s/jx2WZOSLBNy5GN_9elniaw</link><description></description><content:encoded><![CDATA[全市场最强赛道解读①：CXO七龙珠踏上巨头之路]]></content:encoded><pubDate>Tue, 30 Mar 2021 18:58:33 +0800</pubDate></item></channel></rss>